ArticleMycopathologia2020
Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran.
Article in Mycopathologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis.Clinical imaging · 2022Pooled it
- Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2022Pooled it
- Pooled it
- Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Influenza-related invasive pulmonary aspergillosis in an infectious disease ward at a pulmonary referral center in Iran.BMC infectious diseases · 2025Article
- Impact of physician awareness and microbiological examination on incidence of COVID-19-associated pulmonary aspergillosis: a retrospective study.BMC pulmonary medicine · 2025Article
- Identification ofOpen forum infectious diseases · 2024Article
- Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection.Archives of Iranian medicine · 2024Article
- Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.Mycopathologia · 2024Review
- Central nervous system Aspergillus quadrilineatus infection in a COVID-19 patient, a case report and literature review.Journal of clinical laboratory analysis · 2023Review
- Lateral flow assay (LFA) in the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): a single-center experience.BMC infectious diseases · 2022Article
- Black Fungus and beyond: COVID-19 associated infections.Clinical imaging · 2022Review
- COVID-19 co-infection in a patient with brucellosis.Clinical case reports · 2022Article
- Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review.Health science reports · 2022Article
- Multifaceted efficacy of caspofungin against fungal infections in COVID-19 patients.Medical hypotheses · 2022Article
- Clinical and Imaging Features of COVID-19-Associated Pulmonary Aspergillosis.Diagnostics (Basel, Switzerland) · 2022Article
- COVID-19 complicated with chronic necrotizing pulmonary aspergillosis and aspergilloma progressing to fibrosing aspergillosis: A case report.Clinical case reports · 2022Article
- When Viruses Meet Fungi: Tackling the Enemies in Hematology.Journal of fungi (Basel, Switzerland) · 2022Review
- Pathogenesis of Respiratory Viral and Fungal Coinfections.Clinical microbiology reviews · 2022Review
- Cerebral Aspergillosis Complicating COVID Recovery.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Although patients with severe immunodeficiency and hematological malignancies has been considered at highest risk for invasive fungal infection, patients with severe pneumonia due to influenza, and severe acute respiratory syndrome coronavirus (SARS-CoV) are also at a higher risk of developing invasive pulmonary aspergillosis (IPA). Recently, reports of IPA have also emerged among SARS-CoV-2 infected patients admitted to intensive care units (ICUs). Here, we report a fatal case of probable IPA in an acute myeloid leukemia patient co-infected with SARS-CoV-2 and complicated by acute respiratory distress syndrome (ARDS). Probable IPA is supported by multiple pulmonary nodules with ground glass opacities which indicate halo sign and positive serum galactomannan results. Screening studies are needed to evaluate the prevalence of IPA in immunocompromised patients infected with SARS-CoV-2. Consequently, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples of COVID-19 patients with timely and targeted antifungal therapy based on early clinical suspicion of IPA are highly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.